Skip to content
Snippets Groups Projects
Commit ae5e9130 authored by Timofej Paramonov Bliki's avatar Timofej Paramonov Bliki :heart:
Browse files

Added a lot of changes for home, including first draft of home page, images... 

Added a lot of changes for home, including first draft of home page, images and CSS style settings, and fixed to the front page logo.
parent faccb552
No related branches found
No related tags found
1 merge request!23Added a lot of changes for home, including first draft of home page, images...
Pipeline #447681 failed
Stage: build
Hide whitespace changes
Inline Side-by-side
Showing
with 139 additions and 21 deletions
wiki/pages/home.html
+ 139
− 21
View file @ ae5e9130
......@@ -6,19 +6,52 @@
<div>
<div style="display:flex; justify-content: center;">
<img id="back-img" src="https://static.igem.wiki/teams/5342/images/infinityf-nobg-circle.webp" alt="InfinityF logo" style="width:auto; height:auto; max-height:50vh; max-width:70vw; z-index:0;">
<img id="front-img" src="https://static.igem.wiki/teams/5342/images/infinityf-nobg-logos-circle.webp" alt="InfinityF logo" style="width:auto; height:auto; max-height:50vh; max-width:70vw; transition: all 2s; z-index:1; opacity:0; position:absolute;">
<img id="front-img" src="https://static.igem.wiki/teams/5342/images/infinityf-nobg-logos-circle.webp" alt="InfinityF logo" style="width:auto; height:auto; max-height:50vh; max-width:70vw; transition: opacity 4s; z-index:1; opacity:0; position:absolute;">
</div>
<div id="header-text" style="text-align:center; opacity:0; transition: opacity 2s;">
<h1 style="color:white; font-weight:900;" >Our mission:</h1>
<h2 style="color:white; font-weight:bold;">Improve current Haemophilia treatment</h2>
<h1 style="color:white; font-weight:900;" ><i>Our mission:</i></h1>
<h2 style="color:white; font-weight:bold;"><i>Improve current Haemophilia treatment</i></h2>
</div>
</div>
{% endblock %}
{% block page_content %}
<style>
h3 {
color: #e3000b;
/* font-weight: bold; */
font-size: 36pt;
margin-top: 3vh;
}
h4 {
color: #e3000b;
font-size: 20pt;
}
p {
font-size: 15pt;
}
h5 {
color: #730e04;
font-size: 18pt;
}
.text-highlight {
font-weight: bold;
color: #e3000b;
font-size: 18pt;
}
.main-img {
max-height:35vh;
max-width: 90%;
width:auto;
height:auto;
}
.center-div {
display:flex;
justify-content:center;
}
</style>
<script>
document.addEventListener("scroll", () => {
document.addEventListener("DOMContentLoaded", () => {
document.getElementById("front-img").style.opacity='1';
document.getElementById("header-text").style.opacity='1';
}, {once:true});
......@@ -29,29 +62,114 @@
Blood clotting cascade is like a relay race where the runners are clotting factors.
In Haemophilia A, factor 9, after receiving a baton from factor 11, is racing to form a clot that will stop a bleed in a patient.
However, the next member of the race, factor 8, is missing!
The Radboud iGEM team finds a solution to save the day, our improved Haemophilia treatment, InfinitiF∞.
</p>
<p>
The Radboud iGEM team finds a solution to save the day, our improved Haemophilia treatment, InfinityF∞.
</p>
<div style="min-width: 55%; display:flex; justify-content:center;">
<iframe style="max-width:100%;" title="Radboud-University: InfinityF∞: Revolutionizing Hemophilia Treatment with Ioniza... (2024) - Project Promotion [English]" width="560" height="315" src="https://video.igem.org/videos/embed/3c80e512-061f-452c-a2fe-68a25e868175" allow="fullscreen" sandbox="allow-same-origin allow-scripts allow-popups allow-forms"></iframe>
<iframe style="max-width:100%;" title="Radboud-University: InfinityF∞: Revolutionizing Hemophilia Treatment with Ioniza... (2024) - Project Promotion [English]" width="560" height="315" src="https://video.igem.org/videos/embed/3c80e512-061f-452c-a2fe-68a25e868175" allow="fullscreen" sandbox="allow-same-origin allow-scripts allow-popups allow-forms"></iframe>
</div>
</div>
<!-- side-by-side ver.
<div style="display:flex; justify-content: center;">
<div style="min-width: 45%;">
<p>
Blood clotting cascade is like a relay race where the runners are clotting factors.
In Haemophilia A, factor 9, after receiving a baton from factor 11, is racing to form a clot that will stop a bleed in a patient.
However, the next member of the race, factor 8, is missing!
The Radboud iGEM team finds a solution to save the day, our improved Haemophilia treatment, InfinitiF∞.
</p>
</div>
<div style="min-width: 45%; display:flex; justify-content:center;">
<iframe style="max-width:100%;" title="Radboud-University: InfinityF∞: Revolutionizing Hemophilia Treatment with Ioniza... (2024) - Project Promotion [English]" width="560" height="315" src="https://video.igem.org/videos/embed/3c80e512-061f-452c-a2fe-68a25e868175" allow="fullscreen" sandbox="allow-same-origin allow-scripts allow-popups allow-forms"></iframe>
</div>
<h3>What is Haemophilia?</h3>
<h4>Haemophilia A (HemA) is an X-linked hereditary disease that results in insufficient levels of clotting Factor VIII in the blood or deficiency of FVIII function.</h4>
<p>Factor 8 is a large glycoprotein which participates in the intrinsic pathway of the coagulation cascade.</p>
<div class="center-div">
<img src="https://static.igem.wiki/teams/5342/images/home/factor-eight.webp" alt="Factor-Eight Diagram" class="main-img">
<p>[1]</p>
</div>
-->
<p>
In the world, more than 400,000 male patients are living with HemA.
HemA also accounts for 80% of hemophilia cases.
A chance for a newborn male to acquire Haemophilia A is 1 in 5,000–10,000 males with a high risk of patient mortality when undergoing a surgery.
Without treatment, even small bleeds can become dangerous and in serious cases, patients have a high risk of spontaneous bleeding [2, 3].
</p>
<div class="center-div">
<img src="https://static.igem.wiki/teams/5342/images/home/hema-issue.webp" alt="Haemophilia A - Haemophilia patients are unable to form clots in blood vessels." class="main-img">
</div>
<h3>Why improve the current treatment?</h3>
<h4>Current HemA treatment consists of regular injections with Factor VIII protein.</h4>
<p>
And, even though this approach has its benefits: it can be done by the patient themselves and there are possibilities for an implantable port for easy administration, there are still some limitations.
</p>
<div class="center-div">
<img src="https://static.igem.wiki/teams/5342/images/home/injection.webp" alt="Injection diagram" class="main-img">
</div>
<p>
Injections are invasive and uncomfortable, which should always be important to consider when developing a treatment.
On top of that, a Haemophilia patient has to make frequent injections - every 48 hours - to keep their FVIII levels on a normal level.
The frequent injections are in part the result of the high clearance of factor VIII from the circulation with a half-life of 10-12 hours.
This causes the factor VIII concentration in the blood to fluctuate a lot, spiking up after injection, then quickly going down until the next injection.
Currently, there are multiple engineered recombinant factor VIII products available, but these are way more expensive than the cheapest variety of FVIII, which is purified from blood products and already has an annual cost of $300,000!
</p>
<h3>InfinityF∞</h3>
<h4>To solve the problems of the current Haemophilia treatment, the Radboud University team came up with the idea of an innovative medicine: <b>InfinityF∞</b>.</h4>
<div class="center-div">
<img src="https://static.igem.wiki/teams/5342/images/home/new-treatment.webp" alt="Figure illustrating the key elements of the new treatment." class="main-img">
</div>
<p> <span class="text-highlight">InfinityF∞</span> - an intranasal mRNA delivery system for Factor VIII using ionizable lipid nanoparticles.</p>
<p>
We are hoping that this new system will give a more controlled release of factor VIII.
The coolest thing about it is that the nanoparticles are small enough to be delivered via an intranasal route.
</p>
<p style="text-align:center; color:#e3000b">This means patients do not need to get injections anymore, and they can just use a nasal spray!</p>
<h4>How does it work?</h4>
<p>
InfinityF delivers the mRNA sequence for factor VIII encapsulated by a lipid nanoparticle that serves as a carrier for the medicine.
When the nanoparticle reaches its target in the body, the cells will take it up into a lysosome and break the LNP preserving the genetic sequence inside.
After that, the cell produces the protein factor VIII from the mRNA and releases it into the blood.
</p>
<div class="center-div">
<img src="https://static.igem.wiki/teams/5342/images/home/infinityf-method.webp" alt="Diagram that explains the InfinityF delivery process" class="main-img">
</div>
<h4>How do we make it?</h4>
<p>
The factor VIII mRNA is produced with in vitro transcription using factor VIII pcDNA as a template.
Our ionizable lipid nanoparticles contain synthetic lipids as well as an ionizable lipid, which is essential for the release of the mRNA in the cells.
</p>
<div class="center-div">
<img src="https://static.igem.wiki/teams/5342/images/home/factor8-process.webp" alt="FactorVIII process" class="main-img">
</div>
<h4>How do we solve these problems?</h4>
<h5>Invasive</h5>
<p>
The factor VIII mRNA is produced with in vitro transcription using factor VIII pcDNA as a template.
Our ionizable lipid nanoparticles contain synthetic lipids as well as an ionizable lipid, which is essential for the release of the mRNA in the cells.
</p>
<!--<h5>Frequent Injections</h5>-->
<h5>Concentration Spikes</h5>
<p>
Production of protein from mRNA occurs gradually and not in all cells at the same time, spreading out the high concentration spike that occurs after injection of FVIII. €
</p>
<!--<h5>High Clearance</h5>-->
<h5>Cost</h5>
<p>
Costs are very important when speaking about medical treatment.
Since the current Haemophilia medicine utilizes purified protein from human plasma, the price skyrockets to big numbers!
Current price of Haemophilia medicine (in the USA): 8000 euro/week [4].
Estimated price of LNP dosage for InfinityF∞ medicine (for an average patient of 60 kg): 160 euro/week.
</p>
<h3>We are the first iGEM team in Radboud’s History</h3>
<h4>We are the Radboud iGEM Team!</h4>
<p>
The Radboud iGEM team was started by a group of enthusiastic students that were looking to broaden their horizon and start something new.
We hope to introduce the iGEM competition to Radboud university while also putting Radboud university on the map within the iGEM competition.
</p>
<p>
As a new team, we spent a lot of time navigating the organisational aspects within the university as well as familiarizing ourselves with the systems of the competition.
With our efforts, we hope to pave the way for future Radboud iGEM teams.
</p>
<p>
We are beyond excited to showcase InfinityF as the first team to represent Radboud University within the iGEM competition, and it is with passion and determination that we say:
</p>
<h4 style="font-weight: bold; font-style:italic; text-align:center; color:#e3000b" >Let’s synthesize a better future together!</h4>
<h3>References:</h3>
<ol>
<li>..</li>
</ol>
<!--
<div class="row">
<div class="col">
......
0% or .
You are about to add 0 people to the discussion. Proceed with caution.
Finish editing this message first!
Please register or to comment